Paper3929677
Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.
Goldstein EJ and 1 other. Antimicrob Agents Chemother, 1985. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus. Papers, record 3929677. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3929677
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacteria | Major topic |
| Cephalosporins | Major topic |
| Methicillin | Major topic |
| Cefotaxime | |
| Ceftazidime | |
| Enterococcus faecalis | |
| Microbial Sensitivity Tests | |
| Penicillin Resistance | |
| Pseudomonas aeruginosa | |
| Staphylococcus aureus | |
| Staphylococcus epidermidis | |
| Cefpirome |
Source PubMed
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7004294 | The clinical significance of tolerance of Staphylococcus aureus. | Ann Intern Med | 1980 | https://conductscience.org/library/papers/7004294 | PubMed |
| 2 | 6115237 | Enterococcal sensitivity to third generation cephalosporins. | Lancet | 1981 | https://conductscience.org/library/papers/6115237 | PubMed |
| 3 | 7114626 | The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit. | Ann Intern Med | 1982 | https://conductscience.org/library/papers/7114626 | PubMed |
| 4 | 7114635 | Treatment of infections due to methicillin-resistant Staphylococcus aureus. | Ann Intern Med | 1982 | https://conductscience.org/library/papers/7114635 | PubMed |
| 5 | 6294779 | Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. | Rev Infect Dis | 1982 | https://conductscience.org/library/papers/6294779 | PubMed |
| 6 | 6550616 | Resistance of methicillin-resistant staphylococcus aureus to third-generation cephalosporins. | J Infect Dis | 1983 | https://conductscience.org/library/papers/6550616 | PubMed |
| 7 | 6352620 | Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections. | J Antimicrob Chemother | 1983 | https://conductscience.org/library/papers/6352620 | PubMed |
| 8 | 6352651 | Ceftazidime: aspects of efficacy and tolerance. | J Antimicrob Chemother | 1983 | https://conductscience.org/library/papers/6352651 | PubMed |
| 9 | 6352659 | Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. | J Antimicrob Chemother | 1983 | https://conductscience.org/library/papers/6352659 | PubMed |
| 10 | 6611135 | In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6611135 | PubMed |
| 11 | 6593000 | In vitro activity of HR 810, a new cephalosporin. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6593000 | PubMed |
| 12 | 6092278 | Chemotherapeutic properties of the new cephalosporin antibiotic HR810 in laboratory animals. | Infection | 1984 | https://conductscience.org/library/papers/6092278 | PubMed |
| 13 | 6490826 | Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories. | J Clin Microbiol | 1984 | https://conductscience.org/library/papers/6490826 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39664522 | Population pharmacokinetics and dose optimization of ceftazidime in critically ill children. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39664522 | PubMed |
| 10146990 | Drug treatment of pneumonia in the elderly: efficacy and costs. | Pharmacoeconomics | 1993 | https://conductscience.org/library/papers/10146990 | PubMed |
| 8935396 | Nursing home-acquired pneumonia. Treatment options. | Drugs Aging | 1996 | https://conductscience.org/library/papers/8935396 | PubMed |
| 8261711 | Cefpirome clinical pharmacokinetics. | Clin Pharmacokinet | 1993 | https://conductscience.org/library/papers/8261711 | PubMed |
| 2514108 | Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s. | Epidemiol Infect | 1989 | https://conductscience.org/library/papers/2514108 | PubMed |
| 2009876 | Evaluation of two methods for overcoming the antibiotic carry-over effect. | Eur J Clin Microbiol Infect Dis | 1991 | https://conductscience.org/library/papers/2009876 | PubMed |
| 1396760 | Activity of cefpirome combined with beta-lactamase inhibitors and affinity for the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus. | Eur J Clin Microbiol Infect Dis | 1992 | https://conductscience.org/library/papers/1396760 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3929677
GET https://conductscience.org/api/papers/v1/3929677/authors